Analysts at StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a research note issued to investors on Sunday. The brokerage set a "sell" rating on the biotechnology company's stock.
Other analysts have also recently issued research reports about the stock. Stifel Nicolaus cut shares of Genocea Biosciences from a "buy" rating to a "hold" rating in a research report on Friday, April 29th. Robert W. Baird dropped their target price on shares of Genocea Biosciences from $8.00 to $3.00 in a research report on Monday, April 11th. Finally, HC Wainwright cut shares of Genocea Biosciences from a "buy" rating to a "neutral" rating in a research report on Friday, April 29th.
Get Genocea Biosciences alerts:Genocea Biosciences Stock Performance
Shares of Genocea Biosciences stock opened at $0.01 on Friday. The firm has a fifty day moving average of $0.05 and a two-hundred day moving average of $0.60. The stock has a market capitalization of $704,760.00, a price-to-earnings ratio of -0.02 and a beta of 2.26. Genocea Biosciences has a 52 week low of $0.01 and a 52 week high of $2.20. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35.
Insider Activity
In other news, major shareholder Paul Edward Walker sold 5,931,843 shares of the business's stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $0.07, for a total value of $415,229.01. Following the completion of the transaction, the insider now owns 4,445,093 shares of the company's stock, valued at approximately $311,156.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, major shareholder Paul Edward Walker sold 5,931,843 shares of the business's stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $0.07, for a total value of $415,229.01. Following the completion of the transaction, the insider now owns 4,445,093 shares of the company's stock, valued at approximately $311,156.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ali Behbahani sold 4,445,093 shares of the business's stock in a transaction on Wednesday, May 25th. The shares were sold at an average price of $0.08, for a total transaction of $355,607.44. The disclosure for this sale can be found here. Insiders sold 10,537,612 shares of company stock valued at $781,461 in the last quarter. Company insiders own 1.61% of the company's stock.Hedge Funds Weigh In On Genocea Biosciences
A hedge fund recently raised its stake in Genocea Biosciences stock. Commonwealth Equity Services LLC increased its stake in Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the period. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 as of its most recent filing with the Securities and Exchange Commission. 59.25% of the stock is owned by institutional investors.
About Genocea Biosciences
(Get Rating)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Recommended Stories
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Three Watchlist Stocks to Capitalize on Sector Rotation
- MarketBeat: Week in Review 7/18 – 7/22
- Falling Copper Prices Weigh On Freeport McMoran's Earnings, But Long Term Fundamentals Intact
- Snap Stock Falters As Growth Slows To Record Low
- Lackluster Results Provide An Opportunity In Tractor Supply Company
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.